Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Ansell

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Circulation|August 17, 2011
Bleeding in very old patients on vitamin K antagonist therapyJack Ansell
JAMA Internal Medicine|July 14, 2015
The Subtle Benefit of Anticoagulant Therapy for Splanchnic Vein ThrombosisJack Ansell
Current Hematology Reports|September 3, 2004
Long-term, secondary treatment of deep venous thrombosis: do we know the appropriate duration of treatment or therapeutic regimen?Jack Ansell
Circulation|July 20, 2005
Vena cava filters: do we know all that we need to know?Jack Ansell
Disease-A-Month : DM|May 19, 2005
Oral anticoagulants--the old and the newJack Ansell
Current Hematology Reports|September 3, 2004
New anticoagulants and their potential impact on the treatment of thromboembolic diseaseJack Ansell
Clinical Advances in Hematology & Oncology : H&O|August 8, 2007
Recommendations on bleeding and nonbleeding complications of vitamin K antagonistsJack Ansell
Circulation|January 5, 2012
New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillationJack Ansell
Seminars in Vascular Surgery|September 20, 2005
Long-term anticoagulation: the prospects for alternatives to warfarinJack Ansell
Current Hematology Reports|September 1, 2005
Long-term follow-up of patients with vena cava filters for the prevention of pulmonary embolismJack Ansell
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Circulation|August 17, 2011
Bleeding in very old patients on vitamin K antagonist therapyJack Ansell
JAMA Internal Medicine|July 14, 2015
The Subtle Benefit of Anticoagulant Therapy for Splanchnic Vein ThrombosisJack Ansell
Current Hematology Reports|September 3, 2004
Long-term, secondary treatment of deep venous thrombosis: do we know the appropriate duration of treatment or therapeutic regimen?Jack Ansell
Circulation|July 20, 2005
Vena cava filters: do we know all that we need to know?Jack Ansell
Disease-A-Month : DM|May 19, 2005
Oral anticoagulants--the old and the newJack Ansell
Current Hematology Reports|September 3, 2004
New anticoagulants and their potential impact on the treatment of thromboembolic diseaseJack Ansell
Clinical Advances in Hematology & Oncology : H&O|August 8, 2007
Recommendations on bleeding and nonbleeding complications of vitamin K antagonistsJack Ansell
Circulation|January 5, 2012
New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillationJack Ansell
Seminars in Vascular Surgery|September 20, 2005
Long-term anticoagulation: the prospects for alternatives to warfarinJack Ansell
Current Hematology Reports|September 1, 2005
Long-term follow-up of patients with vena cava filters for the prevention of pulmonary embolismJack Ansell
Pageof 12